Author’s response to reviews

Title: Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis

Authors:

Arata Nakajima (a-nakaji@sf7.so-net.ne.jp)
Keiichiro Terayama (kei-tera@sakura.med.toho-u.ac.jp)
Masato Sonobe (masato0609@aol.com)
Yasuchika Aoki (yasuaoki35@sf4.so-net.ne.jp)
Hiroshi Takahashi (hiroshi.takahashi@med.toho-u.ac.jp)
Yorikazu Akatsu (yorikazu.akatsu@med.toho-u.ac.jp)
Junya Saito (junya.saito@med.toho-u.ac.jp)
Shinji Taniguchi (shinji.taniguchi@med.toho-u.ac.jp)
Manabu Yamada (manabu.yamada@med.toho-u.ac.jp)
Ayako Kubota (ayakokubota@med.toho-u.ac.jp)
Koichi Nakagawa (konakag@med.toho-u.ac.jp)

Version: 1 Date: 26 Jun 2019

Author’s response to reviews:

1. Overlap
We revised our manuscript so that we could avoid textual overlap with other previously published works.

2. Title page
We revised the corresponding author information provided on the title page.

3. Ethics approval and consent to participate
We included the full name of the ethics committee that approved the study and the committee’s reference number.

In the “ethical approval and consent to participate” section, we stated that informed consent obtained was written.
4. Consent for publication
We included a ‘Consent for publication’ section in the Declarations and stated “Not Applicable” in this section.

5. Funding
In the Funding section, we described that the corresponding author (AN) was funded by a Grant-in-Aid for scientific research of Japan, and stated the role of the corresponding author in this study.

6. Acknowledgements
We included an acknowledgements section and stated ‘Not Applicable’ in this section.

7. Formatting
-- In your Abstract, please rename your "Objectives" heading to "Background".
-- In your main manuscript body, please rename your "Introduction" heading to "Background".
-- In your main manuscript body, please rename your "Patients and methods" heading to "Methods" only.
-- Please include a separate Conclusion section with a "Conclusion" heading.
-- Please move your Abbreviations so they are before your Declarations section.
We revised our manuscript according to the directions described above.